Editas Medicine Inc. (EDIT)
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.43 per share a year ago.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.55 per share a year ago.
Top 3 Genomics Stocks to Consider for Your Portfolio
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.75 per share a year ago.
Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?
Gene editing seems like a great idea: Instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as Crispr. I previously covered two companies, Crispr Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a Crispr licensee. But it failed twice, with treatments aimed at eye disease and sickle cell disease/beta thalassemia. And its stock suffered badly.
